Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

Haug, Alexander; Auernhammer, Christoph J.; Wängler, Björn; Tiling, Reinhold; Schmidt, Gerwin P.; Göke, Burkhard; Bartenstein, Peter; Pöpperl, Gabriele

doi:10.1007/s00259-008-1030-8

Cited by 200 publications

(110 citation statements)

References 12 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…68 Ga-DOTATATE PET/CT showed high sensitivity (.94%) and specificity (.92%) for NEN lesion localization, with the highest accuracy being for primary midgut tumors. The results of that study are in line with those of much smaller previous studies using PET/CT with either 68 Ga-DOTATOC or 68 Ga-DOTANOC (16,20,(43)(44)(45)(46). Overall, SSR PET/CT showed a high accuracy ($96%) for the detection of welldifferentiated NENs at either the primary site or the metastatic sites (mostly lymph nodes, liver, bone, and lung) (20,39,44).…”

Section: Clinical Valuesupporting

confidence: 87%

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

et al. 2017

View full text Add to dashboard Cite

CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA category 1 credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through November 2020.68 Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor-expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history; the histopathology and biomarker information; and the grade, stage, and prior imaging results. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false-positive results. This article provides a guide to the performance and interpretation of 68 Ga-DOTATATE PET/CT and describes its role in the diagnostic algorithm of neuroendocrine neoplasms and its overall utility in their management.

show abstract

Section: Clinical Valuesupporting

confidence: 87%

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Somatostatin receptor PET has shown promising results in NETs, with a higher lesion detection rate than is achieved with 18 F-fluorodihydroxyphenyl-L-alanine PET, somatostatin receptor SPECT, CT, or MR imaging (10,11,22,23). Currently, 68 Ga-DOTATOC, 68 Ga-DOTATATE, and 68 Ga-DOTANOC are the most established somatostatin receptor PET tracers (13 68 Ga-DOTATATE and 68 Ga-DOTANOC) showed a similar diagnostic accuracy for these tracers for the detection of NETs.…”

Section: Discussionmentioning

confidence: 99%

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

et al. 2013

View full text Add to dashboard Cite

Somatostatin receptor PET tracers such as [ 68 Ga-DOTA, 1-Nal 3 ]-octreotide ( 68 Ga-DOTANOC) and [ 68 Ga-DOTA,Tyr 3 ]-octreotate ( 68 Ga-DOTATATE) have shown promising results in patients with neuroendocrine tumors, with a higher lesion detection rate than is achieved with 18 F-fluorodihydroxyphenyl-Lalanine PET, somatostatin receptor SPECT, CT, or MR imaging. 68 Ga-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst 2,3,5 ). It has a wider receptor binding profile than 68 Ga-DOTATATE, which is sst 2 -selective. The wider receptor binding profile might be advantageous for imaging because neuroendocrine tumors express different subtypes of somatostatin receptors. The goal of this study was to prospectively compare 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT in the same patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to evaluate the clinical impact of 68 Ga-DOTANOC PET/CT. Methods: Eighteen patients with biopsy-proven GEP-NETs were evaluated with 68 Ga-DOTANOC and 68 Ga-DOTATATE using a randomized crossover design. Labeling of DOTANOC and DOTATATE with 68 Ga was standardized using a fully automated synthesis device. PET/CT findings were compared with 3-phase CT scans and in some patients with MR imaging, 18 F-FDG PET/CT, and histology. Uptake in organs and tumor lesions was quantified and compared by calculation of maximum standardized uptake values (SUVmax) using volume computer-assisted reading. Results: Histology revealed low-grade GEP-NETs (G1) in 4 patients, intermediate grade (G2) in 7, and high grade (G3) in 7. 68 Ga-DOTANOC and 68 Ga-DOTATATE were false-negative in only 1 of 18 patients. In total, 248 lesions were confirmed by crosssectional and PET imaging. The lesion-based sensitivity of 68 Ga-DOTANOC PET was 93.5%, compared with 85.5% for 68 Ga-DOTATATE PET (P 5 0.005). The better performance of 68 Ga-DOTANOC PET is attributed mainly to the significantly higher detection rate of liver metastases rather than tumor differentiation grade. Multivariate analysis revealed significantly higher SUVmax in G1 tumors than in G3 tumors (P 5 0.009).This finding was less pronounced with 68 Ga-DOTANOC (P . 0.001). Altogether, 68 Ga-DOTANOC changed treatment in 3 of 18 patients (17%). Conclusion: The sst 2,3,5 -specific radiotracer 68 Ga-DOTANOC detected significantly more lesions than the sst 2 -specific radiotracer 68 Ga-DOTATATE in our patients with GEP-NETs. The clinical relevance of this finding has to be proven in larger studies.

show abstract

“…Imaging of gastroenteropancreatic NETs SRS as discussed earlier appear to be comparable or better than DOPA PET. In a head to head comparison between 68Ga-DOTATATE and 18F-DOPA PET in the diagnosis of differentiated metastatic NETs, patient-based sensitivities were 96% for 68Ga-DOTATATE compared with 56% for 18F-DOPA, with 68Ga-DOTATATE PET proving clearly superior for detection and staging of NETs [77] . In addition, the clinical impact of PET-based SRS has been established in several publications, and the added advantage of SRS is that it allows the suitability assessment for peptide receptor radionuclide therapy, something that DOPA PET does not allow.…”

Section: A B Cmentioning

confidence: 93%

Imaging of gastroenteropancreatic neuroendocrine tumors

Tan

Tan²

2011

WJCO

View full text Add to dashboard Cite

Imaging of gastroenteropancreatic neuroendocrine tumors can be broadly divided into anatomic and functional techniques. Anatomic imaging determines the local extent of the primary lesion, providing crucial information required for surgical planning. Functional imaging, not only determines the extent of metastatic disease spread, but also provides important information with regard to the biologic behavior of the tumor, allowing clinicians to decide on the most appropriate forms of treatment. We review the current literature on this subject, with emphasis on the strengths of each imaging modality.

show abstract

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

Cited by 200 publications

References 12 publications

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

Imaging of gastroenteropancreatic neuroendocrine tumors

Contact Info

Product

Resources

About

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours

Cited by 200 publications

References 12 publications

Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

Imaging of gastroenteropancreatic neuroendocrine tumors

Contact Info

Product

Resources

About

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Current Concepts in ⁶⁸Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors